Several other research analysts have also commented on AERI. BidaskClub lowered shares of Aerie Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, August 7th. HC Wainwright set a $78.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 9th. Cowen lifted their price objective on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the stock a buy rating in a research note on Thursday, August 9th. Canaccord Genuity reaffirmed a buy rating and set a $86.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, August 10th. Finally, ValuEngine upgraded Aerie Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $79.25.
NASDAQ AERI opened at $40.43 on Monday. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -12.00 and a beta of 0.92. Aerie Pharmaceuticals has a 52 week low of $38.50 and a 52 week high of $74.75.
In other Aerie Pharmaceuticals news, Director Gerald D. Cagle bought 2,000 shares of the firm’s stock in a transaction dated Friday, November 16th. The stock was acquired at an average cost of $41.75 per share, for a total transaction of $83,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Casey C. Kopczynski sold 11,000 shares of Aerie Pharmaceuticals stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $39.81, for a total value of $437,910.00. Following the sale, the insider now owns 118,042 shares of the company’s stock, valued at $4,699,252.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,117 shares of company stock valued at $7,784,846. Corporate insiders own 10.53% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in AERI. Vanguard Group Inc. raised its holdings in shares of Aerie Pharmaceuticals by 12.7% in the third quarter. Vanguard Group Inc. now owns 3,887,580 shares of the company’s stock valued at $239,281,000 after acquiring an additional 436,964 shares in the last quarter. Frontier Capital Management Co. LLC bought a new stake in shares of Aerie Pharmaceuticals in the second quarter valued at about $24,685,000. Provident Investment Management Inc. bought a new stake in shares of Aerie Pharmaceuticals in the third quarter valued at about $16,120,000. BlackRock Inc. raised its holdings in shares of Aerie Pharmaceuticals by 9.0% in the second quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock valued at $202,049,000 after acquiring an additional 246,686 shares in the last quarter. Finally, PointState Capital LP raised its holdings in shares of Aerie Pharmaceuticals by 524.7% in the second quarter. PointState Capital LP now owns 281,600 shares of the company’s stock valued at $19,022,000 after acquiring an additional 236,524 shares in the last quarter.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Story: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.